New cholesterol drug put to the test in major chinese heart study
NCT ID NCT06941792
Summary
This study is comparing a newer cholesterol-lowering injection called inclisiran against standard care for patients in China with coronary heart disease. It aims to see if inclisiran is more effective at lowering 'bad' cholesterol (LDL-C) over one year in a real-world setting. The trial will also check how well patients stick to their treatment and monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigated Site
Taiyuan, Shanxi, 030000, China
-
Novartis Investigative Site
Anqing, Anhui, 246003, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 102218, China
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 400010, China
-
Novartis Investigative Site
Longyan, Fujian, 364099, China
-
Novartis Investigative Site
Jiamusi, Heilongjiang, 154002, China
-
Novartis Investigative Site
Zhengzhou, Henan, 451400, China
-
Novartis Investigative Site
Baotou, Inner Mongolia, 014010, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110016, China
-
Novartis Investigative Site
Shenyang, Liaoning, 121100, China
-
Novartis Investigative Site
Jining, Shandong, 272000, China
-
Novartis Investigative Site
Weifang, Shandong, 261000, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200065, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610031, China
-
Novartis Investigative Site
Ürümqi, Xinjiang Uygur Autonomous Region, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310007, China
-
Novartis Investigative Site
Jinhua, Zhejiang, 321000, China
-
Novartis Investigative Site
Ningbo, Zhejiang, 315000, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
Conditions
Explore the condition pages connected to this study.